top of page
Executive Spotlights

Abivax Appoints Marc de Garidel as Chief Executive Officer and Interim Board Chair

Paris, France, April 5, 2023 (Accesswire) -- Abivax SA, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Marc de Garidel as Chief Executive Officer (CEO) and Interim Board Chair, effective May 5, 2023.


Read full article here.

Recent Posts

See All

Comments


Life Science Headlines
bottom of page